Real‐World Effectiveness of Rebamipide on Gastritis Symptoms: A Patient‐Focused Approach [PDF]
Clinical and Translational ScienceRebamipide is a gastric mucosal protectant used to relieve gastritis symptoms. Real‐world evidence on the comparative effectiveness of rebamipide monotherapy versus combination therapy with proton‐pump inhibitors (PPIs) in routine clinical settings is ...
Hyun Ji Woo +3 more
doaj +3 more sources
Rebamipide (Mucosta®), a clinically approved drug, alleviates neuroinflammation and dopaminergic neurodegeneration in a Parkinson’s disease model [PDF]
Journal of NeuroinflammationBackground Parkinson’s disease (PD) is characterized by dopaminergic neuron loss, neuroinflammation, and motor dysfunction. PD is a multifactorial disease, with neuroinflammation driven by NLRP3 inflammasome activation representing an important component
Hye-Sun Lim +6 more
doaj +2 more sources
Rebamipide for Managing Dyspeptic Symptoms During Proton-Pump Inhibitor Washout Before Helicobacter pylori Testing: A Randomized, Double-Blind, Placebo-Controlled Trial [PDF]
The Turkish Journal of GastroenterologyBackground/Aims: Persistent dyspeptic symptoms are common during the proton pump inhibitor (PPI) washout period before Helicobacter pylori (H. pylori) testing. However, the role of rebamipide in symptom management during this interval remains unclear.
Nottawan Suksai +4 more
doaj +2 more sources
Rebamipide as an Adjunctive Therapy for Gastrointestinal Diseases: An Umbrella Review [PDF]
PharmaceuticalsObjective: This umbrella review aimed to synthesize evidence from meta-analyses on the efficacy of rebamipide in major gastrointestinal disorders and dyspeptic symptoms.
Igor V. Maev +6 more
doaj +2 more sources
In Silico Preformulation Modeling, Solubility Enhancement, and Sustainable Release of Rebamipide Utilizing Deep Eutectic Mixture Loaded Bioadhesive Controlled Release Granules for Gastritis Treatment [PDF]
PharmaceuticsBackground/Objectives: Rebamipide is a gastroprotective agent with poor aqueous solubility and rapid gastrointestinal clearance, leading to reduced therapeutic efficiency.
Yasir Qasim Almajidi +2 more
doaj +2 more sources
Novel Sustained-Release Drug Delivery System for Dry Eye Therapy by Rebamipide Nanoparticles
Pharmaceutics, 2020 The commercially available rebamipide ophthalmic suspension (CA-REB) was approved for clinical use in patients with dry eye; however, the residence time on the ocular surface for the traditional formulations is short, since the drug is removed from the ...
Noriaki Nagai +2 more
exaly +3 more sources
Pharmaceuticals, 2023 Dry eye disease (DED) is one of the most common eye diseases caused by multiple factors. Rebamipide, which is currently used to treat peptic ulcer disease, was shown to enhance secretory function and modulate inflammation in animal disease models ...
Sungyeun Bae +4 more
doaj +1 more source
Rebamipide treatment ameliorates obesity phenotype by regulation of immune cells and adipocytes.
PLoS ONE, 2022 Obesity is a medical term used to describe an over-accumulation of adipose tissue. It causes abnormal physiological and pathological processes in the body.
JooYeon Jhun +9 more
doaj +1 more source
Pharmaceuticals, 2023 Rebamipide is a quinolone derivative that has been commonly used for the treatment of gastric and duodenal ulcers. However, the molecular mechanisms of rebamipide against acetic acid-evoked colitis have not been adequately examined.
Maha M. Abdel-Fattah +6 more
doaj +1 more source
Consilium Medicum, 2022 Aim. To perform a meta-analysis of the data on Rebamipide efficacy and safety as a part of Helicobacter pylori eradication therapy in Russian patients. Materials and methods.
Dmitry N. Andreev +6 more
doaj +1 more source